Please login to the form below
Seattle Genetics
This page shows the latest Seattle Genetics news and features for those working in and with pharma, biotech and healthcare.
Merck signs separate agreements with Seattle Genetics for two cancer drugs
Seattle Genetics will also be eligible for further progress-dependent milestone payments of up to $2.6bn. ... Seattle Genetics will receive $85m in prepaid research and development payments to be applied to Merck’s global development funding obligations
Latest news
-
Seattle Genetics wins FDA priority review for oral HER2 drug
If approved will compete with AZ/Daiichi Sankyo's Enhertu. Seattle Genetics has scored a US Food and Drug Administration (FDA) priority review for its oral HER2 inhibitor tucatinib in breast ... Seattle is seeking approval for tucatinib in combination
-
Seattle Genetics makes case for Padcev plus Keytruda in first-line bladder cancer
Seattle Genetics and partner Astellas have reported positive results from an early clinical trial of their antibody drug conjugate Padcev in combination with Merck &Co/MSD’s Keytruda in first-line ... line setting," said Roger Dansey, chief medical
-
AZ, Daiichi Sankyo get early okay for DS-8201, now named Enhertu
In the meantime, further HER2 competition could be coming from Seattle Genetics’ oral drug tucatinib, which recently cleared the phase 3 HER2CLIMB trial as an add-on to Herceptin plus
-
J&J taps TARIS Biomedical for novel bladder cancer technology
However, J&J is not alone in the bladder cancer market. Seattle Genetics and Astellas claimed approval in the US for Padcev (enfortumab vedotin) last week, as a later-line therapy
-
Seattle, Astellas bag speedy FDA okay for bladder cancer drug
Plans to expand use into earlier bladder cancer treatment. Seattle Genetics and Astellas have claimed approval in the US for Padcev, an antibody-drug conjugate (ADC), as a later-line therapy ... That would drive a sizeable step up in Seattle’s turnover,
Seattle Genetics wins FDA priority review for oral HER2 drug
Seattle Genetics makes case for Padcev plus Keytruda in first-line bladder cancer
AZ, Daiichi Sankyo get early okay for DS-8201, now named Enhertu
J&J taps TARIS Biomedical for novel bladder cancer technology
More from news
Approximately 12 fully matching, plus 27 partially matching documents found.
Latest Intelligence
-
Deal Watch January 2018
Acquisition company. 628. Cascadian Therapeutics/Seattle Genetics. Lead programme tucatinib, oral, small molecule TKI highly selective for HER2 (p2). ... Winding back to last February (DW Issue 80), Immunomedics announced a licensing agreement with
-
Deal Watch March 2017
In an unusual development, the recent licensing deal between Immunomedics and Seattle Genetics, whereby Seattle Genetics is to pay $250m in cash, up to $1.7bn in milestones, and royalties, has ... sacituzumab govitecan after announcing the deal with
-
Deal Watch February 2017
Competitive deal tendering and investor revolt. One of the largest therapeutic deals in February was the Immunomedics licence with Seattle Genetics for a phase 2 stage antibody drug conjugate (ADC), sacituzumab ... Acquisition - company. 2, 475.
-
Pharma deals in June 2015
NewCo formation, collaboration. 760. Unum Therapeutics/ Seattle Genetics. Antibody-coupled T-cell receptor technology for 2 antibodies (platform).
-
Deal Watch table for September 2014
244. Seattle Genetics / Genmab. Licence and collaboration. Additional deal to use Seattle's antibody drug conjugate technology.
Deal Watch March 2017
Deal Watch table for September 2014
More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.
Latest appointments
-
BMS appoints new commercial leader, Davies joins Eisai and more
Prior to this, he served as executive vice president of commercial for Seattle Genetics, where he led all commercial activities for the company.
-
Douglas Williams named president and CEO of Codiak
These included serving as chief scientific officer and executive vice president of research and development at Seattle Genetics and as senior vice president and Washington site leader at Amgen.
-
VentiRx appoints James Kyle Bryan as chief medical officer
Dr Bryan joins from Seattle Genetics, where he served as VP, medical affairs and before that as VP of global product development.
BMS appoints new commercial leader, Davies joins Eisai and more
Douglas Williams named president and CEO of Codiak
VentiRx appoints James Kyle Bryan as chief medical officer
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
-
Digital account director
-
Competitive
-
Events Executive
-
Depending on Experience
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- Understanding the ‘real world’ starts and ends with the patient
- FDA advisory committee votes against approval of AZ, FibroGen's roxadustat
- J&J and Pfizer quietly resolve Remicade biosimilar lawsuit
- CONGREGO™ IS NOW MULTI-PLATFORM
- Onyx Health Marks Record Growth with Six New Appointments
- FDA expands use of COVID-19 antibody cocktail
- New European supply deals show Pfizer and Moderna have increased COVID-19 vaccine prices
- Ipsen’s spending spree bolsters neurology pipeline
- AMICULUM® launches Cence, a new specialist publications agency
- The future of office working designed with our people in mind: ‘Work Where You Work Best’, an Evoke KYNE model
- GSK, Vir’s sotrovimab cuts hospitalisation and death risk by 79% in COVID-19 outpatients
- Biogen and Ionis post ‘encouraging’ early results for Alzheimer’s disease candidate
- Eylea set to challenge Lucentis in UK after NICE recommendation
- Onyx Health Launch Creative Studio After Record Year
- BioNTech to use mRNA technology to develop a ‘highly effective’ malaria vaccine
PMHub
Dovetail
We’re a specialist health consultancy that supports companies, healthcare professionals and patients to work hand in hand with a common...
Latest intelligence
- Guide
- How to embrace behavioural science principles in healthcare MR...
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
